CY2245B1 - Treatment of incontinence with venlafaxine or an aryloxy propanamine compound - Google Patents
Treatment of incontinence with venlafaxine or an aryloxy propanamine compoundInfo
- Publication number
- CY2245B1 CY2245B1 CY0100037A CY0100037A CY2245B1 CY 2245 B1 CY2245 B1 CY 2245B1 CY 0100037 A CY0100037 A CY 0100037A CY 0100037 A CY0100037 A CY 0100037A CY 2245 B1 CY2245 B1 CY 2245B1
- Authority
- CY
- Cyprus
- Prior art keywords
- venlafaxine
- aryloxy
- incontinence
- treatment
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15812193A | 1993-11-24 | 1993-11-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY2245B1 true CY2245B1 (en) | 2003-07-04 |
Family
ID=22566762
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY0100037A CY2245B1 (en) | 1993-11-24 | 2001-11-14 | Treatment of incontinence with venlafaxine or an aryloxy propanamine compound |
CY2005002C CY2005002I2 (el) | 1993-11-24 | 2005-02-10 | Χρηση της βενλαφαξινης ή μιας ενωσης αρυλοξυ προπαναμινης για την παρασκευη ενος φαρμακου για την αγωγη της ουρικης ακρατειας |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY2005002C CY2005002I2 (el) | 1993-11-24 | 2005-02-10 | Χρηση της βενλαφαξινης ή μιας ενωσης αρυλοξυ προπαναμινης για την παρασκευη ενος φαρμακου για την αγωγη της ουρικης ακρατειας |
Country Status (28)
Country | Link |
---|---|
US (1) | US5744474A (de) |
EP (1) | EP0654264B1 (de) |
JP (1) | JP3681009B2 (de) |
KR (1) | KR100347277B1 (de) |
CN (1) | CN1099284C (de) |
AT (1) | ATE201594T1 (de) |
AU (1) | AU679269B2 (de) |
CA (1) | CA2136120C (de) |
CY (2) | CY2245B1 (de) |
CZ (1) | CZ289069B6 (de) |
DE (2) | DE69427337T2 (de) |
DK (1) | DK0654264T3 (de) |
ES (1) | ES2157958T3 (de) |
GE (1) | GEP20064000B (de) |
GR (1) | GR3036446T3 (de) |
HK (1) | HK1013799A1 (de) |
HU (1) | HU218920B (de) |
IL (1) | IL111705A (de) |
LU (1) | LU91140I2 (de) |
NL (1) | NL300174I2 (de) |
NO (2) | NO313535B1 (de) |
PH (1) | PH30741A (de) |
PT (1) | PT654264E (de) |
RU (1) | RU2152786C2 (de) |
SI (1) | SI0654264T1 (de) |
TW (1) | TW344661B (de) |
UA (1) | UA32429C2 (de) |
ZA (1) | ZA949190B (de) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506270A (en) * | 1995-01-30 | 1996-04-09 | American Home Products Corporation | Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women |
DE69721747T2 (de) * | 1996-03-11 | 2004-04-01 | Eli Lilly And Co., Indianapolis | Methode zur behandlung oder verhütung von interstitieller blasenentzundung |
PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
EP1331003B1 (de) * | 1996-03-25 | 2015-08-26 | Wyeth LLC | Venlafaxinhaltige Arzneizusammensetzung mit verzögerter Wirkstoffabgabe |
US6150396A (en) * | 1997-03-07 | 2000-11-21 | Eli Lilly And Company | Methods of treating or preventing interstitial cystitis |
US6579899B1 (en) | 1998-07-16 | 2003-06-17 | Massachusetts Institute Of Technology | Composition for treatment of stress |
WO2000003701A1 (en) * | 1998-07-16 | 2000-01-27 | Massachusetts Institute Of Technology | Composition for treatment of stress |
EP2153825A1 (de) * | 1998-08-27 | 2010-02-17 | Pfizer Health AB | Therapeutische Formulierung zur Verabreichung von Tolterodin mit kontrollierter Freisetzung |
US6046242A (en) * | 1998-11-27 | 2000-04-04 | Basf Aktiengesellschaft | Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence |
US6197828B1 (en) | 1998-12-01 | 2001-03-06 | Sepracor, Inc. | Derivatives of (+)-venlafaxine and methods of preparing and using the same |
US6342533B1 (en) * | 1998-12-01 | 2002-01-29 | Sepracor, Inc. | Derivatives of (−)-venlafaxine and methods of preparing and using the same |
PL350924A1 (en) | 1999-04-06 | 2003-02-10 | Sepracor Inc | Derivatives of venlafaxine and methods of preparing and using the same |
CA2643231A1 (en) | 1999-07-01 | 2001-01-11 | Pharmacia & Upjohn Company | Norepinephrine reuptake inhibitors and methods of using the same |
US7291646B2 (en) | 1999-11-24 | 2007-11-06 | Wyeth | Ethers of O-desmethyl venlafaxine |
US6572890B2 (en) * | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
DE10027290C2 (de) | 2000-06-02 | 2002-07-11 | Basf Coatings Ag | Pulverklarlackdispersionen (Pulverslurry-Klarlacke) und ihre Verwendung |
DE10059412A1 (de) | 2000-11-30 | 2002-06-13 | Gruenenthal Gmbh | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie der Harninkontinenz |
CN100567253C (zh) * | 2001-02-12 | 2009-12-09 | 惠氏公司 | 新的o-去甲基-文拉法辛的琥珀酸盐 |
US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
HUP0402524A2 (hu) * | 2001-12-05 | 2005-03-29 | Wyeth | Venlafaxin-hidroklorid kristályos polimorf formája, eljárások előállítására, az ezt tartalmazó gyógyszerkészítmények és alkalmazásuk |
UA77234C2 (en) * | 2001-12-05 | 2006-11-15 | Wyeth Corp | Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants) |
GB0202265D0 (en) * | 2002-01-31 | 2002-03-20 | Arachnova Therapeutics Ltd | New therapeutic use |
WO2003082805A1 (en) * | 2002-03-28 | 2003-10-09 | Synthon B.V. | Low water-soluble venlafaxine salts |
WO2003090743A1 (en) * | 2002-04-24 | 2003-11-06 | Cypress Bioscience, Inc. | Prevention and treatment of functional somatic disorders, including stress-related disorders |
DE10224107A1 (de) * | 2002-05-29 | 2003-12-11 | Gruenenthal Gmbh | Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz |
US20040197397A1 (en) * | 2002-08-30 | 2004-10-07 | Watson Pharmaceuticals, Inc. | Drug delivery system for treatment of urinary incontinence |
GB0221438D0 (en) | 2002-09-16 | 2002-10-23 | Avecia Ltd | Processes and compounds |
EP1424079A1 (de) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors |
US20070077301A1 (en) * | 2002-12-23 | 2007-04-05 | Meyer Glenn A | Venlafaxine osmotic device formulation |
JP2006522144A (ja) * | 2003-04-04 | 2006-09-28 | ダイノゲン ファーマシューティカルズ,インコーポレイテッド | 下部尿路障害の治療方法 |
GEP20084550B (en) * | 2004-04-30 | 2008-11-25 | Warner Lambert Co | Substituted morpholine compounds for the treatment of central nervous system disorders |
JP5173190B2 (ja) * | 2004-08-25 | 2013-03-27 | 武田薬品工業株式会社 | 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法 |
WO2006071868A2 (en) * | 2004-12-23 | 2006-07-06 | Teva Pharmaceutical Industries Ltd. | Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof |
MX2007011254A (es) | 2005-03-14 | 2007-10-18 | Teva Pharma | Proceso para la preparacion de (s)-(+)-n,n-dimetil-3-(1- naftaleniloxi)-3-(2-tienil)propanamina opticamente activa. |
EP1838692A2 (de) | 2005-09-22 | 2007-10-03 | Teva Pharmaceutical Industries Ltd | Dnt-maleat und herstellungsverfahren dafür |
US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
HUE027865T2 (en) | 2005-12-01 | 2016-11-28 | Auspex Pharmaceuticals Inc | Substituted phenyl ethylamines with serotonergic and / or norepinephrine activity |
EP1863782A1 (de) * | 2005-12-05 | 2007-12-12 | Teva Pharmaceutical Industries Ltd. | 2-(n-methyl-propanamin)-3-(2-naphthol) thiophen, eine verunreinigung von duloxetin hydrochlorid |
EP1957470A1 (de) | 2005-12-05 | 2008-08-20 | Wyeth | Verfahren zur selektiven synthese von enantiomeren aus substituierten 1-(2-amino-1-phenyl-ethyl)-cyclohexanolen |
EP1826204A1 (de) | 2006-02-28 | 2007-08-29 | Laboratorios Del Dr. Esteve, S.A. | Verfahren zur Herstellung enantomerer Ausgangsverbindungen von Duloxetin |
US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
TW200846305A (en) | 2007-03-15 | 2008-12-01 | Auspex Pharmaceuticals Inc | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
EP3820563A4 (de) | 2018-07-11 | 2022-05-04 | Dignify Therapeutics, LLC | Verfahren zur behandlung von entleerungsdysfunktion |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
US4018895A (en) * | 1974-01-10 | 1977-04-19 | Eli Lilly And Company | Aryloxyphenylpropylamines in treating depression |
ZA817863B (en) * | 1980-11-14 | 1983-06-29 | Lilly Co Eli | (-)n-methyl-3-(2-methylphenoxy)-3-phenylpropylamnie,antidepressant |
IE56324B1 (en) * | 1982-12-13 | 1991-06-19 | American Home Prod | Phenethylamine derivatives and intermediates therefor |
US4761501A (en) * | 1983-10-26 | 1988-08-02 | American Home Products Corporation | Substituted phenylacetamides |
KR880007433A (ko) * | 1986-12-22 | 1988-08-27 | 메리 앤 터커 | 3-아릴옥시-3-치환된 프로판아민 |
US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
PT87163B (pt) * | 1987-04-09 | 1992-07-31 | Lilly Co Eli | Processo para a preparacao de 1-fenil-3-naftaleniloxi-propanaminas |
SE8804003D0 (sv) * | 1988-11-04 | 1988-11-04 | Pharmacia Ab | Compounds for the treatment of urinary incontinence |
US5250571A (en) * | 1988-11-14 | 1993-10-05 | Eli Lilly And Company | (S)-norfluoxetine in method of inhibiting serotonin uptake |
CA2061665C (en) * | 1991-02-25 | 2002-04-16 | Mark Mortensen Foreman | Treatment of lower urinary tract disorders |
EP0537915B1 (de) * | 1991-09-27 | 1995-07-12 | Eli Lilly And Company | N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)Propylamine als Norepinephrineinhibitoren |
US5281624A (en) * | 1991-09-27 | 1994-01-25 | Eli Lilly And Company | N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof |
US5192751A (en) * | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
-
1994
- 1994-05-12 TW TW083104298A patent/TW344661B/zh not_active IP Right Cessation
- 1994-11-18 CA CA002136120A patent/CA2136120C/en not_active Expired - Lifetime
- 1994-11-18 ZA ZA949190A patent/ZA949190B/xx unknown
- 1994-11-21 UA UA94119056A patent/UA32429C2/uk unknown
- 1994-11-21 NO NO19944456A patent/NO313535B1/no not_active IP Right Cessation
- 1994-11-21 PH PH49414A patent/PH30741A/en unknown
- 1994-11-21 IL IL11170594A patent/IL111705A/en not_active IP Right Cessation
- 1994-11-22 KR KR1019940030696A patent/KR100347277B1/ko not_active IP Right Cessation
- 1994-11-22 AU AU78968/94A patent/AU679269B2/en not_active Expired
- 1994-11-22 DE DE69427337T patent/DE69427337T2/de not_active Expired - Lifetime
- 1994-11-22 SI SI9430379T patent/SI0654264T1/xx unknown
- 1994-11-22 DE DE1994627337 patent/DE122005000005I2/de active Active
- 1994-11-22 EP EP94308604A patent/EP0654264B1/de not_active Expired - Lifetime
- 1994-11-22 ES ES94308604T patent/ES2157958T3/es not_active Expired - Lifetime
- 1994-11-22 PT PT94308604T patent/PT654264E/pt unknown
- 1994-11-22 DK DK94308604T patent/DK0654264T3/da active
- 1994-11-22 AT AT94308604T patent/ATE201594T1/de active
- 1994-11-22 JP JP28811994A patent/JP3681009B2/ja not_active Expired - Lifetime
- 1994-11-23 CZ CZ19942893A patent/CZ289069B6/cs not_active IP Right Cessation
- 1994-11-23 HU HU9403369A patent/HU218920B/hu unknown
- 1994-11-23 CN CN94118993A patent/CN1099284C/zh not_active Expired - Lifetime
- 1994-11-23 RU RU94041950/14A patent/RU2152786C2/ru active
-
1995
- 1995-04-20 US US08/425,703 patent/US5744474A/en not_active Expired - Lifetime
-
1998
- 1998-12-23 HK HK98115196A patent/HK1013799A1/xx not_active IP Right Cessation
-
2001
- 2001-08-27 GR GR20010401296T patent/GR3036446T3/el unknown
- 2001-11-14 CY CY0100037A patent/CY2245B1/xx unknown
-
2005
- 2005-02-04 LU LU91140C patent/LU91140I2/fr unknown
- 2005-02-09 NO NO2005004C patent/NO2005004I1/no unknown
- 2005-02-10 CY CY2005002C patent/CY2005002I2/el unknown
- 2005-02-10 NL NL300174C patent/NL300174I2/nl unknown
-
2006
- 2006-05-23 GE GEAP20069411A patent/GEP20064000B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2245B1 (en) | Treatment of incontinence with venlafaxine or an aryloxy propanamine compound | |
TW224942B (de) | ||
AU3107993A (en) | Method of treating hyperproliferative vascular disease | |
IL102414A0 (en) | Method of treating ocular inflammation | |
IN176618B (de) | ||
GR3018226T3 (en) | Sulfonanilide derivative and medicine. | |
NZ247406A (en) | Treatment of osteoporosis with 1 alpha, 24(r)-dihydroxy-22(e)-dehydro-vitamin d3 | |
AU609637B2 (en) | Process for the treatment of effluents containing cyanide and/or other oxidizable substances | |
ZA941729B (en) | Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5). | |
AU7375994A (en) | Treatment of cyanides in effluents with caro's acid | |
EP0338532A3 (de) | Tricyclische aromatische N-Alkylamino Derivaten zur Behandlung von Arzneimittel resistent protozuen Infektionen | |
IN184221B (de) | ||
AU7719491A (en) | Therapeutic compound | |
CA2561293A1 (en) | Treatment of incontinence | |
AU1282592A (en) | Method for treatment for neuro-muscular incontinence | |
AU5051090A (en) | A method of treatment or prevention of post-PTCA restenosis by post-PTCA restenosis inhibitor |